McKinney Diana L, Cassidy Michael P, Collier Lauren M, Martin Billy R, Wiley Jenny L, Selley Dana E, Sim-Selley Laura J
Department of Pharmacology and Toxicology, Virginia Commonwealth University, Box 980524, 1112 East Clay St., Richmond, VA 23298, USA.
J Pharmacol Exp Ther. 2008 Feb;324(2):664-73. doi: 10.1124/jpet.107.130328. Epub 2007 Oct 29.
Chronic treatment with Delta(9)-tetrahydrocannabinol (THC) produces tolerance to cannabinoid-mediated behaviors and region-specific adaptation of brain cannabinoid receptors. However, the relationship between receptor adaptation and tolerance is not well understood, and the dose-response relationship of THC-induced cannabinoid receptor adaptation is unknown. This study assessed cannabinoid receptor function in the brain and cannabinoid-mediated behaviors after chronic treatment with different dosing regimens of THC. Mice were treated twice per day for 6.5 days with the following: vehicle, 10 mg/kg THC, or escalating doses of 10 to 20 to 30 or 10 to 30 to 60 mg/kg THC. Tolerance to cannabinoid-mediated locomotor inhibition, ring immobility, antinociception, and hypothermia was produced by both ramping THC-dose paradigms. Administration of 10 mg/kg THC produced less tolerance development, the magnitude of which depended upon the particular behavior. Decreases in cannabinoid-mediated G-protein activation, which varied with treatment dose and region, were observed in autoradiographic and membrane guanosine 5'-O-(3-[(35)S]thio)triphosphate ([(35)S]GTPgammaS)-binding assays in brains from THC-treated mice. Agonist-stimulated [(35)S]GTPgammaS binding was reduced in the hippocampus, cingulate cortex, periaqueductal gray, and cerebellum after all treatments. Decreased agonist-stimulated [(35)S]GTPgammaS binding in the caudate-putamen, nucleus accumbens, and preoptic area occurred only after administration of 10 to 30 to 60 mg/kg THC, and no change was found in the globus pallidus or entopeduncular nucleus after any treatment. Changes in the CB(1) receptor B(max) values also varied by region, with hippocampus and cerebellum showing reductions after all treatments and striatum/globus pallidus showing effects only at higher dosing regimens. These results reveal that tolerance and CB(1) receptor adaptation exhibit similar dose-dependent development, and they are consistent with previous studies demonstrating less cannabinoid receptor adaptation in striatal circuits.
长期使用 Δ⁹-四氢大麻酚(THC)会导致对大麻素介导行为产生耐受性,并使脑内大麻素受体出现区域特异性适应性变化。然而,受体适应性与耐受性之间的关系尚未完全明确,THC 诱导的大麻素受体适应性的剂量反应关系也不清楚。本研究评估了用不同剂量方案长期处理 THC 后,脑内大麻素受体功能及大麻素介导的行为。小鼠每天接受两次处理,持续 6.5 天,处理方式如下:溶剂对照组、10 mg/kg THC,或递增剂量的 10 至 20 至 30 或 10 至 30 至 60 mg/kg THC。两种递增 THC 剂量模式均产生了对大麻素介导的运动抑制、环形不动、抗伤害感受和体温过低的耐受性。给予 10 mg/kg THC 产生的耐受性发展较少,其程度取决于具体行为。在用 THC 处理的小鼠脑内进行的放射自显影和膜鸟苷 5'-O-(3-[(³⁵)S]硫代)三磷酸([(³⁵)S]GTPγS)结合试验中,观察到大麻素介导的 G 蛋白激活减少,其随处理剂量和区域而变化。所有处理后,海马体、扣带回皮质、导水管周围灰质和小脑中激动剂刺激的[(³⁵)S]GTPγS 结合减少。仅在给予 10 至 30 至 60 mg/kg THC 后,尾状核-壳核、伏隔核和视前区中激动剂刺激的[(³⁵)S]GTPγS 结合减少,而在任何处理后苍白球或内囊核均未发现变化。CB₁ 受体 Bmax 值的变化也因区域而异,所有处理后海马体和小脑均显示降低,而纹状体/苍白球仅在较高剂量方案下显示出影响。这些结果表明,耐受性和 CB₁ 受体适应性表现出相似的剂量依赖性发展,并且与先前显示纹状体回路中大麻素受体适应性较低的研究一致。